MX2023009681A - Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon. - Google Patents
Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon.Info
- Publication number
- MX2023009681A MX2023009681A MX2023009681A MX2023009681A MX2023009681A MX 2023009681 A MX2023009681 A MX 2023009681A MX 2023009681 A MX2023009681 A MX 2023009681A MX 2023009681 A MX2023009681 A MX 2023009681A MX 2023009681 A MX2023009681 A MX 2023009681A
- Authority
- MX
- Mexico
- Prior art keywords
- lung
- compositions
- treatment methods
- tl1a antibodies
- tl1a
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150832P | 2021-02-18 | 2021-02-18 | |
| US202163180896P | 2021-04-28 | 2021-04-28 | |
| US202163226041P | 2021-07-27 | 2021-07-27 | |
| US202163285785P | 2021-12-03 | 2021-12-03 | |
| PCT/US2022/016840 WO2022178158A1 (en) | 2021-02-18 | 2022-02-17 | Anti-tl1a antibody compositions and methods of treatment in the lung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009681A true MX2023009681A (es) | 2023-10-30 |
Family
ID=82931034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009681A MX2023009681A (es) | 2021-02-18 | 2022-02-17 | Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240336691A1 (https=) |
| EP (1) | EP4294443A4 (https=) |
| JP (1) | JP2024508762A (https=) |
| KR (1) | KR20230158494A (https=) |
| AU (1) | AU2022221712A1 (https=) |
| BR (1) | BR112023016574A2 (https=) |
| CA (1) | CA3207818A1 (https=) |
| MX (1) | MX2023009681A (https=) |
| TW (1) | TW202302640A (https=) |
| WO (1) | WO2022178158A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| JP2022533956A (ja) | 2019-05-14 | 2022-07-27 | プロメテウス バイオサイエンシーズ，インク． | Ｔｌ１ａ患者を選択する方法、システム、およびデバイス |
| KR20220103721A (ko) | 2019-10-24 | 2022-07-22 | 프로메테우스 바이오사이언시즈, 인크. | Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도 |
| EP4665394A2 (en) * | 2023-02-17 | 2025-12-24 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment in the kidney |
| EP4665395A1 (en) * | 2023-02-17 | 2025-12-24 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment in the liver |
| AU2024222357A1 (en) * | 2023-02-17 | 2025-08-28 | Cedars-Sinai Medical Center | Anti-tl1a antibody compositions and methods of treating skin |
| WO2024186859A2 (en) * | 2023-03-09 | 2024-09-12 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment for sarcoidosis |
| CN121843714A (zh) | 2023-08-11 | 2026-04-10 | 派拉冈医疗公司 | Tl1a结合抗体及使用方法 |
| US12473370B2 (en) | 2023-10-03 | 2025-11-18 | Absci Corporation | TL1A associated antibody compositions and methods of use |
| TW202545995A (zh) | 2024-01-26 | 2025-12-01 | 大陸商明濟生物製藥(北京)有限公司 | 能夠與ｔｌ１ａ特異性結合之抗體及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080233119A2 (en) * | 2003-08-20 | 2008-09-25 | University Of Miami | Compositions and methods for treating inflammatory lung disease |
| WO2009114110A1 (en) * | 2008-03-08 | 2009-09-17 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| JO3375B1 (ar) * | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| EA201591153A1 (ru) * | 2013-01-02 | 2016-01-29 | Гленмарк Фармасьютикалс С.А. | Антитела, связывающиеся с tl1a, и их применение |
| MX388027B (es) * | 2013-11-13 | 2025-03-19 | Pfizer | Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos. |
| TWI703158B (zh) * | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| MY191324A (en) * | 2016-10-26 | 2022-06-15 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
| US10626180B2 (en) * | 2017-04-20 | 2020-04-21 | Cedars-Sinai Medical Center | Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease |
| JP7332627B2 (ja) * | 2018-04-25 | 2023-08-23 | プロメテウス バイオサイエンシーズ，インク． | 最適化された抗ｔｌ１ａ抗体 |
| JP2022533956A (ja) * | 2019-05-14 | 2022-07-27 | プロメテウス バイオサイエンシーズ，インク． | Ｔｌ１ａ患者を選択する方法、システム、およびデバイス |
| KR20220103721A (ko) * | 2019-10-24 | 2022-07-22 | 프로메테우스 바이오사이언시즈, 인크. | Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도 |
-
2022
- 2022-02-17 CA CA3207818A patent/CA3207818A1/en active Pending
- 2022-02-17 AU AU2022221712A patent/AU2022221712A1/en active Pending
- 2022-02-17 TW TW111105899A patent/TW202302640A/zh unknown
- 2022-02-17 EP EP22756948.0A patent/EP4294443A4/en active Pending
- 2022-02-17 JP JP2023549819A patent/JP2024508762A/ja active Pending
- 2022-02-17 KR KR1020237031713A patent/KR20230158494A/ko active Pending
- 2022-02-17 WO PCT/US2022/016840 patent/WO2022178158A1/en not_active Ceased
- 2022-02-17 BR BR112023016574A patent/BR112023016574A2/pt unknown
- 2022-02-17 MX MX2023009681A patent/MX2023009681A/es unknown
- 2022-02-17 US US18/546,947 patent/US20240336691A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3207818A1 (en) | 2022-08-25 |
| WO2022178158A1 (en) | 2022-08-25 |
| BR112023016574A2 (pt) | 2023-11-21 |
| AU2022221712A1 (en) | 2023-09-21 |
| EP4294443A4 (en) | 2025-08-20 |
| TW202302640A (zh) | 2023-01-16 |
| EP4294443A1 (en) | 2023-12-27 |
| JP2024508762A (ja) | 2024-02-28 |
| KR20230158494A (ko) | 2023-11-20 |
| US20240336691A1 (en) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023009681A (es) | Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon. | |
| SA520420801B1 (ar) | أil جسام مضادة لـ -11 | |
| SA522432691B1 (ar) | المركبات الحلقية الماكروية وطرق العلاج المرتبطة بها | |
| CY1122456T1 (el) | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου | |
| BR112022003956A2 (pt) | Anticorpos anti-cd73 | |
| EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
| MX2022014914A (es) | Compuestos de interaccion con glicanos y metodos de uso. | |
| MX2022005256A (es) | Inhibidores de cd73. | |
| BR112016030541A2 (pt) | métodos para o tratamento de infecções fúngicas | |
| JOP20220119A1 (ar) | أجسام مضادة trem2 واستخداماتها | |
| EP4603508A3 (en) | Anti-frizzled antibodies and methods of use | |
| EP3603636A4 (en) | COMPOSITION TARGETING S1PR4 TO PREVENT OR TREAT NON-ALCOHOLIC STEATOHEPATITIS | |
| CY1124238T1 (el) | Χρηση αντισωματων κατα της σκληροστινης στη θεραπεια της ατελους οστεογενεσης | |
| ZA202103867B (en) | Tubulysins and protein-tubulysin conjugates | |
| CL2022003715A1 (es) | Tubulisinas y conjugados de proteinas-tubulisina | |
| MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
| MX2021010665A (es) | Metodos de tratamiento de amiloidosis al. | |
| EA202192400A1 (ru) | Антитела против интегрина и их применение | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
| UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
| CL2022000967A1 (es) | Composiciones y métodos para el tratamiento de enfermedades hepáticas | |
| BR112023017556A2 (pt) | Anticorpo contra nkp46 e aplicação do mesmo | |
| EA202190807A1 (ru) | Антитела к синуклеину | |
| EP3817749A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | |
| EA201992626A1 (ru) | Способы и композиции для лечения аллергических заболеваний глаз |